



## Summary of NICE Guidelines

Title	Bivalirudin for the treatment of ST-segment-elevation myocardial infarction.
NICE Reference	NICE technology appraisal guidance 230 (TA230)
Date of Review:	July-2014
Date of Publication	July-2011
Summary of Guidance	<ul style="list-style-type: none"><li>• Bivalirudin is a direct thrombin inhibitor.</li><li>• Bivalirudin is already in use in the UK and both patients and clinicians are in favour of its continued use. Bivalirudin is easier to use than abciximab (glycoprotein IIb/IIIa inhibitor) because the solution is easier to prepare and administer.</li><li>• The <b>clinical effectiveness</b> of bivalirudin in combination with aspirin and clopidogrel is based on evidence from the HORIZONS-AMI trial that compared a strategy of bivalirudin with one using heparin plus glycoprotein IIb/IIIa inhibitors (both treatment arms receiving aspirin and clopidogrel). The primary outcome of major bleeding and secondary outcomes of all-cause mortality and cardiac mortality showed statistically significant advantages for treatment with bivalirudin over treatment with heparin plus glycoprotein IIb/IIIa inhibitor.</li><li>• <b>Cost effectiveness:</b> The NICE Evidence Review Group (ERG) conducted exploratory analyses to check that the manufacturer's submitted economic analysis was robust. The ERG was satisfied that the manufacturer's model, which suggests that a bivalirudin-based intervention dominates heparin plus glycoprotein IIb/IIIa inhibitor, was robust to sensitivity analyses.</li><li>• <b>Key Conclusion:</b> Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of adults with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (sometimes called balloon angioplasty or stenting).</li></ul>
Impact on Lab (See below)	■ None
Lab professionals to be made aware	Not applicable.
Please detail the impact of this guideline.	No impact.

### **Impact on Lab**

- None:** This NICE guideline has no impact on the provision of laboratory services
- Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

**Produced by:** Phillip Monaghan

**Reviewed by:** Dr Joanne Adaway